Nanodermatology Society announces agenda for its annual meeting

(Nanowerk News) The Nanodermatology Society invites you to attend their third annual scientific conference in conjunction with the American Academy of Dermatology annual meeting at the Lowes Miami Beach Hotel, Miami Florida, March 3 th 2013, 7:30-9:30 am, Poinciana 4 room. Seating is limited, so please reserve your place.
For this coming year we have lined up an outstanding faculty of international nanotechnology experts from industry, academia, and government to speak on clinically important topics and on new and emerging technologies including: nanodrug delivery for cutaneous disease, cosmeceuticals employing nanotechnology, and sunscreens. The current agenda includes
7:30 AM Dr. Heidi Kong – Microbiome
Dr. Kong received her undergraduate degree in biological sciences from Stanford University and obtained her M.D. from Baylor College of Medicine. She then completed her dermatology residency at Duke University. After completing clinical research fellowship in the Dermatology Branch and the Duke-NIH Masters Program in Clinical Research, Dr. Kong became an Assistant Clinical Investigator and worked with collaborators including Julian Segre to establish the NIH Intramural Skin Microbiome Consortium. She is currently a tenure-track clinical investigator. Dr. Kong will discuss the cutaneous microbiome in healthy skin, in skin disease, and the role of microbiome study in elucidating the pathogenesis of dermatologic disorders.
7:50 AM Dr. Michael Wilkerson – Photoactivation
Dr. Wilkerson is Associate Professor of Dermatology, Vice Chair for Clinical Affairs, and Medical Director of Dermatology Clinics in the Department of Dermatology at the University of Texas Medical Branch in Galveston. His research interests include penetration of nanoparticles in the skin, their reactivity in vitro and in vivo, their effects on cells and tissues, their mutagenicity, and toxicity. Dr. Wilkerson will be discussing studies of photoactivated nanoparticle.
Wang S, Hunter LA, Arslan Z, Wilkerson MG, Wickliffe JK. Chronic exposure to nanosized, anatase titanium dioxide is not cyto- or genotoxic to Chinese hamster ovary cells. Environ Mol Mutagen. 2011 Oct;52(8):614-22
Choksi AN, Poonawalla T, Wilkerson MG. Nanoparticles: a closer look at their dermal effects. J Drugs Dermatol. 2010 May;9(5):475-81.
8:10 AM Dr. Zoe Draelos – Nanometals
Dr. Draelos, a Rhodes Scholar, received her undergraduate degree in mechanical engineering at the University of Arizona, Tucson and her MD at the University of Arizona College of Medicine in Tucson, where she completed her internship in internal medicine and dermatology residency. Dr. Draelos has been principal investigator in a number of clinical trials, has served on the editorial board of national and international scientific journals including the Journal of the American Academy of Dermatology, and has had academic appointments at Wake Forest University and Duke University. Dr. Draelos is the author of over two hundred publications, twelve books, and has presented at numerous national and international conferences. She has chaired a number of advisory committees at the American Academy of Dermatology and has served as the Vice President of the American Academy of Dermatology. Dr. Draelos will be discussing nanometals in dermatology.
Draelos ZD. Reinvigorating cosmetic dermatology with the nanoparticle revolution. J Cosmet Dermatol. 2011 Dec;10(4):251-2.
Draelos ZD. The multifunctional value of sunscreen-containing cosmetics. Skin Therapy Lett. 2011 Jul-Aug;16(7):1-3.
8:30 AM Dr. Annika Vogt – Topical vaccination
Dr. Vogt is an investigator and Scientific Director for Experimental Research at the Clinical Research Center for Hair and Skin Science, and Center of Experimental and Applied Cutaneous Physiology, Department of Dermatology and Allergy, Charité—Universitaetsmedizin Berlin. Dr. Vogt’s early interests included studies with Dr. Earvin Epstein on the immunoprevention of basal cell carinomas with recombinant hedgehog-interacting proteins. She worked with Dr. Thomas Luger on the role of melanocortin receptors in human dermal papilla cells. Her most recent interests have included the application of topical nanoparticles for transcutaneous immunization. Dr. Vogt will talk about strategies for epicutaneous vaccination.
Papakostas D, Rancan F, Sterry W, Blume-Peytavi U, Vogt A. Nanoparticles in dermatology. Arch Dermatol Res. 2011 Oct;303(8):533-50.
Liard C, Munier S, Joulin-Giet A, Bonduelle O, Hadam S, Duffy D, Vogt A, Verrier B, Combadière B. Intradermal immunization triggers epidermal Langerhans cell mobilization required for CD8 T-cell immune responses. J Invest Dermatol. 2012 Mar;132(3 Pt 1):615-25.
8:50 AM Dr. Fiorenza Rancan – Follicle Targeting
Dr. Rancan is Senior Research Investigator at the Department of Dermatology and Allergy, Charite-Universitaetsmedizin Berlin. Her early work includes studies of fullerenes and phototoxicity. She has subsequently explored the roles of fullerene conjugates for photodynamic therapy. Her most recent work includes the analysis and development of nanoparticles for topical application and local dermatotherapy through the exploitation of hair follicle targeting. Dr. Rancan will discuss drug delivery through the follicular pathway.
Rancan F, Todorova A, Hadam S, Papakostas D, Luciani E, Graf C, Gernert U, Rühl E, Verrier B, Sterry W, Blume-Peytavi U, Vogt A. Stability of polylactic acid particles and release of fluorochromes upon topical application on human skin explants. Eur J Pharm Biopharm. 2012 Jan;80(1):76-84
Rancan F, Gao Q, Graf C, Troppens S, Hadam S, Hackbarth S, Kembuan C, Blume-Peytavi U, Rühl E, Lademann J, Vogt A. Skin penetration and cellular uptake of amorphous silica nanoparticles with variable size, surface functionalization, and colloidal stability. ACS Nano. 2012 Aug 28;6(8):6829-42.
9:10 AM Dr. Gil Yosipovitch – Small Molecules in Itch
Dr. Yosipovitch is Professor of Dermatology at Wake Forest University. He has joint appointments at the Comprehensive Cancer Center, the Center for Biomolecular Imaging, the Center for Integrative Medicine, the Department of Neurobiology & Anatomy, and the Institute for Regenerative Medicine. Dr. Yosipovitch completed his B.Sc. at Hebrew University Hadassah and his medical degree at Tel Aviv University Sackler School of Medicine, where he completed his internship in internal medicine and his dermatology residency. He did his fellowship training in dermatology at the University of California School of Medicine in San Francisco. An expert on itch and its central and peripheral mechanisms, he is the author of more than two hundred and fifty articles in books and peer-reviewed publications. He serves on the editorial board of seven dermatology journals including the Journal of the American Academy of Dermatology. He is the recipient of several prestigious awards for his research including the Rothschild Foundation award, and the Heinz Maurer Prize. Dr.Yosipovitch is the Principal Investigator for a RO1 NIH grant dedicated to the investigation of peripheral and central neural mechanisms of chronic pruritus. The studies conducted in his group employ brain imaging techniques (functional MRI), itch psychophysics, skin micro dialysis, tape stripping, and heart rate variability (HRV). Dr. Yosipovitch organized the first International Workshop for the Study of Itch in Singapore in 2001, and is the founder and past president of the International Forum for the Study of Itch (IFSI), which is a multidisciplinary international association of clinicians and researchers dedicated to improving our understanding of itch. He is the editor of a textbook: Itch Basic Mechanisms and Treatment. He will discuss new small molecules as current and future targets for the treatment of itch.
Papoiu AD, Wang H, Nattkemper L, Tey HL, Ishiuji Y, Chan YH, Schmelz M, Yosi-povitch G. A study of serum concentrations and dermal levels of NGF in atopic dermatitis and healthy subjects. Neuropeptides. 2011 Dec;45(6):417-22.
Tey HL, Yosipovitch G. Targeted treatment of pruritus: a look into the future. Br J Dermatol. 2011 Jul;165(1):5-17.
Source: Nanodermatology Society